ReviewBone marrow transplantation2016
What do we need to know about allogeneic hematopoietic stem cell transplant survivors?
Review in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Are tomorrow's doctors ready to donate? Insights into medical students' knowledge and attitudes on stem cell donation: a cross-sectional study.BMC medical education · 2026Article
- Article
- Acute graft-versus-host disease.Nature reviews. Disease primers · 2023Review
- Antiviral treatment causes a unique mutational signature in cancers of transplantation recipients.Cell stem cell · 2021Article
- Bone Marrow Transplantation as Therapy for Ataxia-Telangiectasia: A Systematic Review.Cancers · 2020Review
- Clinical and Genetic Risk Prediction of Cognitive Impairment After Blood or Marrow Transplantation for Hematologic Malignancy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- Gonadal failure among female patients after hematopoietic stem cell transplantation for non-malignant diseases.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2019Article
- Palliative care during and following allogeneic hematopoietic stem cell transplantation.Current opinion in supportive and palliative care · 2018Review
- [How I treat chronic graft-versus-host disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2018Article
- Measurement of Hyperglycemia and Impact on Health Outcomes in People With Cancer: Challenges and Opportunities.Oncology nursing forum · 2017Review
- Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for over 70 benign and malignant hematologic and immunological processes. Over the past several decades, significant technological and post-transplant supportive advances have been made, resulting in a decrease in early transplant mortality and continued growth in the population of allo-HSCT survivors. With the expansion in the number of long-term survivors, as well as of those considering a transplant, the focus of transplant medicine has been shifted significantly to include a more prominent role for the care of the 'long-term' survivor. These patients have survived the acute critical phase of transplantation and have potentially achieved remission from their primary disease, yet allo-HSCT patients do not return to pre-transplant health status. For survivors >2 years removed, the time of transplant all-cause mortality is four- to nine-fold higher than age-matched peers within the general population. These patients represent a distinct, high-risk population that must be monitored for long-term transplant complications, including chronic GvHD (cGvHD), multi-organ dysfunctions and secondary malignancies. This article will review in a non-exhaustive manner, the approach to long-term care of an allo-HSCT recipient.
Indexed as
Identifiers
27064688What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.